Antiviral Drugs on the Treatment of SARS-CoV-2
Completed
- Conditions
- Pneumonia, ViralComplication of Medical Care
- Interventions
- Registration Number
- NCT04727775
- Lead Sponsor
- Astana Medical University
- Brief Summary
Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases
- Detailed Description
Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
main group
- Patients with COVID19 with medium and easy condition disease
- take favipiravir/remdisivir control group
- Patients with COVID19 with medium and easy condition disease
- not take favipiravir/remdisivir
Exclusion Criteria
- patients younger 18
- severe conditionis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Oxygen status Remdesivir Evaluathion Oxugen support Favipiravir Evaluathion Complications Remdesivir Evaluathion Oxygen status Favipiravir Evaluathion Complications Favipiravir Evaluathion Oxugen support Remdesivir Evaluathion
- Primary Outcome Measures
Name Time Method Outcome without comlications 14 days The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2
- Secondary Outcome Measures
Name Time Method SpO2 14 days Measure
Respiratory rate 14 days Measure
Heart rate 14 days Measure
Blood pressure 14 days Measure
Trial Locations
- Locations (2)
Semey Medical University
🇰🇿Semey, Kazakhstan
Aidos Konkaev
🇰🇿Astana, Kazakhstan